SCHEDULE: Armistice Capital Boosts Verrica Stake to 9.99%
Beneficial Ownership Statement
Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9.99% of Verrica Pharmaceuticals Inc.'s common stock as of March 31, 2025.
Summary
- Armistice Capital, LLC and Steven Boyd collectively own 9,235,571 shares of Verrica Pharmaceuticals Inc. common stock.
- This ownership represents 9.99% of the company's outstanding common stock.
- The shares are held with shared voting power and shared dispositive power.
- The ownership is certified as a passive investment, acquired and held in the ordinary course of business, and not for the purpose of changing or influencing control of the issuer.
- Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
- Steven Boyd is the managing member of Armistice Capital, LLC.
Sentiment
Score: 6
Explanation: Neutral to slightly positive. While a Schedule 13G is a factual disclosure of ownership, a significant institutional stake (9.99%) by a recognized investment firm like Armistice Capital can be interpreted as a vote of confidence in the company's prospects, even if it's a passive investment.
Positives
- A significant institutional stake of 9.99% by Armistice Capital, LLC and Steven Boyd may signal confidence in Verrica Pharmaceuticals Inc.'s long-term prospects.
Future Outlook
No forward-looking statements or guidance are provided in this beneficial ownership filing.
Industry Context
This filing indicates continued institutional interest in Verrica Pharmaceuticals, a company operating within the pharmaceutical sector. Such Schedule 13G filings are standard disclosures for investment firms acquiring significant passive stakes in publicly traded companies, reflecting their portfolio positioning rather than operational updates.
Stakeholder Impact
- Shareholders: Indicates a significant institutional investor holds a substantial stake, potentially signaling confidence or stability in the shareholder base.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which required the filing of this statement. |
| 05/15/2025 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Verrica Pharmaceuticals, Armistice Capital, Steven Boyd, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Pharmaceuticals, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.